Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambitol Fiber is a combination pharmaceutical product developed by Ambiens Pharmaceuticals, primarily indicated for the management of chronic constipation. It consists of two active components: lactitol monohydrate and ispaghula husk (also known as psyllium). Lactitol is a synthetic disaccharide that functions as an osmotic laxative; it remains unabsorbed in the upper gastrointestinal tract and is fermented by colonic bacteria into organic acids, which increases osmotic pressure and draws water into the intestinal lumen. Ispaghula husk is a bulk-forming laxative that absorbs water to form a mucilaginous mass, thereby increasing stool volume and stimulating natural bowel movements. The synergistic effect of these two ingredients helps to soften the stool and improve colonic transit time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactitol + ispaghula husk.